InPharma

Dear network, it is a pleasure to share with you my recently published article on "Abiraterone acetate fixed-dosed combinations with ibuprofen-based therapeutic eutectic and deep eutectic solvents". This formulation serves as another approach to developing enabling formulations based on deep eutectic solvents. Specifically, this approach enhances solubility of poorly soluble compounds by utilizing an API-incorporated deep eutectic solvent (so-called therapeutic deep eutectic solvent, THEDES) to dissolve a second poorly soluble drug with pharmaceutically synergistic effect. Special thanks to my supervisors Prof. Dr. Martin Kuentz and Dr. Josef Beranek for their invaluable supervision and great support throughout the project. Looking forward to future research advancing the understanding of pharmaceutically applicable enabling deep eutectic solvents. Please have a read at this new approach to formulating stubborn new API candidates! 😊 https://lnkd.in/e86BG5g7

Upcoming phD Defence: Matteo Guidetti, Physics, Chemistry and Pharmacy, University of Southern Denmark, will defend his PhD on Friday 20 December at 11.30 in DIAS Seminar room.   In connection with the PhD defense the following lecture will take place: ”Pharmaceutical co-crystals”

I am thrilled to announce that I received the Poster Award at the EUFEPS Annual Conference 2024! 🏆 The conference was a great opportunity to discuss the latest research with pharmaceutical scientists from all over the world! I saw many stimulating posters from other awardees and feel honoured to be among them. Many thanks to the coauthors Patrick O'Dwyer, Josef Beranek, Martin Kuentz, Brendan Griffin and the InPharma research consortium!

Congratulations to Shirin Nika Dietrich for successfully defending her PhD!

📢 Interview with Malte Bøgh S. for the #InPharma On-the-Job Series In the latest feature of our InPharma on-the-job series, we had the opportunity to speak with Malte Bøgh Senniksen, our Early Stage Researcher (#ESR) 12, about his experience in the InPharma project. Malte is pioneering an animal-free modelling approach for developing amorphous solid dispersions, advancing research towards more ethical and innovative solutions in pharmaceutical development. Malte began his journey in August 2021 at Fraunhofer ITMP in Frankfurt, Germany, where he dedicated 13 months to his research. He has since transitioned to F. Hoffmann – La Roche in Basel, Switzerland, where he will complete the remainder of his PhD. This international experience is core to the InPharma approach, which is designed as a European Industrial Doctorate (EID) programme, integrating both academic and industry training. ESRs like Malte split their time between academic institutions and industry partners, gaining interdisciplinary skills and hands-on experience in a real-world setting. Our InPharma on-the-job series aims to shed light on the experiences of our ESRs within this unique programme, offering insights into the benefits and challenges of industry-focused doctoral training. Read the full interview here: https://lnkd.in/efAcjVRq #InPharma #PharmaResearch #ESR #PhDLife #onthejob

🎓✨ Successful PhD Defense! ✨🎓 I am happy to share that I had my PhD defense last month and have earned my PhD degree. I am incredibly grateful to be at this point after three intense, but rewarding years of research, learning and growth. My work was focused on the impact of digestion on the performance of lipid-based formulations including the development of a novel in vitro lipolysis-permeation model. This journey would not have been possible without the support of so many amazing people. First and foremost, a sincere ‘thank you’ to my supervisors - Annette Bauer-Brandl, René Holm, Martin Brandl and Jef Stappaerts for their support, guidance and trust. I was fortunate to experience the best of both worlds during my PhD: spending half of my time in industry with the incredible Biopharm team at Johnson & Johnson in Belgium and the other half in academia with the Drug Transport & Delivery group at SDU in Denmark. To my colleagues at J&J and SDU, thank you for being so welcoming and for teaching me so many things along the way – and, of course, for this unique and personal PhD hat. It was a great experience to be part of the InPharma consortium and to form a team with my wonderful fellow ESRs. The training sessions and collaborations with scientists from academia and industry across Europe, through annual meetings and discussions, were truly invaluable. Lastly, I want to thank the assessment committee for their time, effort and dedication during my defense. 

🎈 PhD Defense coming up: Felix Christian Paulus, Physics, Chemistry and Pharmacy, University of Southern Denmark, will defend his PhD on Thursday 10 October at 14.30 in Karen Brahe Auditoriet, Adelige Jomfrukloster/Noble Virgin Convent Odense, Albani Torv 6, 5000 Odense. In connection with the PhD defense the following lecture will take place: The role of digestion on the performance of enabling formulations.

I am happy to share our latest research paper titled “Using the refined Developability Classification System (rDCS) to guide the design of oral formulations”. This work has been published in The Journal of Pharmaceutical Sciences (JPharmSci) and is accessible via the following link: https://lnkd.in/eWkCbX5S In this paper, we explore application of the rDCS, an animal-free in vitro framework for evaluating the biopharmaceutics risks of novel active pharmaceutical ingredients (APIs) in relation to oral absorption. Our findings showcase how rDCS analysis can provide tailored guidance for designing optimal oral formulations. 💡 Key takeaways: 📈 Recent advances in the rDCS framework: We present recent key advances in the rDCS scientific framework. 🌍 Real-world application: We applied the rDCS to six diverse compounds, demonstrating its practical use in optimizing oral formulations strategies. 🏭 Industry impact: We hope this work encourages both smaller companies and larger pharmaceutical organizations to adopt the rDCS framework in their development processes. 🧠 rDCS vs. BCS: Insights provided by the rDCS analysis are compared with those generated by the BCS. I would like to extend a special thanks to Prof. Jennifer Dressman, as well as our co-authors Eline Hermans, Kia Sepassi and René Holm for their contributions. This work is part of the InPharma European Industrial Doctorate Program, funded by the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie grant agreement No 955756.

🔬 Meet Lotte Ejskjær, an #InPharma Early Stage Researcher! She’s investigating the use of precipitation inhibitors in lipid-based formulations to enhance drug absorption. Lotte spent 18 months at University College Cork c and is now at Johnson & Johnson Innovative Medicine in Belgium for the remainder of her PhD. As part of our on-the-job series, we interviewed Lotte to share her experience of working within an industry-focused doctoral training programme. Stay tuned! https://lnkd.in/evEgFXUe #InPharma #PharmaResearch #ESR #PhDLife #LipidFormulations #PharmaInnovation

📢 Interview with Egis Zeneli as part of the #InPharma On-the-Job Series 📢 We are thrilled to feature Egis, one of our InPharma Early Stage Researchers (ESR 6), in our latest on-the-job interview! 🙌 Egis is currently working on developing computational methods for supersaturating drug delivery systems, tackling the solubility challenges of many active pharmaceutical ingredients (APIs). During her time with InPharma, Egis was hosted at the University of Applied Sciences and Arts Northwestern Switzerland FHNW and The Janssen Pharmaceutical Companies of Johnson & Johnson, gaining invaluable experience in both academic and industrial settings. Check out the interview to learn more about Egis's journey and her experiences working within an industry-focused doctoral training programme! 🎓💡 https://lnkd.in/eFydiV7D #InPharma #PharmaResearch #ESR #DrugDelivery #AIinPharma #CareerInResearch #DoctoralTraining #PharmaInnovation #PhDLife